Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 114

1.

Clinical significance and prognostic value of Triosephosphate isomerase expression in gastric cancer.

Chen T, Huang Z, Tian Y, Lin B, He R, Wang H, Ouyang P, Chen H, Wu L.

Medicine (Baltimore). 2017 May;96(19):e6865. doi: 10.1097/MD.0000000000006865.

2.

A guide to the effects of a large portion of the residues of triosephosphate isomerase on catalysis, stability, druggability, and human disease.

Olivares-Illana V, Riveros-Rosas H, Cabrera N, Tuena de Gómez-Puyou M, Pérez-Montfort R, Costas M, Gómez-Puyou A.

Proteins. 2017 Jul;85(7):1190-1211. doi: 10.1002/prot.25299. Epub 2017 Apr 27. Review.

PMID:
28378917
3.

In silico prediction of the effects of mutations in the human triose phosphate isomerase gene: Towards a predictive framework for TPI deficiency.

Oliver C, Timson DJ.

Eur J Med Genet. 2017 Jun;60(6):289-298. doi: 10.1016/j.ejmg.2017.03.008. Epub 2017 Mar 21.

PMID:
28341520
4.

Triosephosphate isomerase 1 suppresses growth, migration and invasion of hepatocellular carcinoma cells.

Jiang H, Ma N, Shang Y, Zhou W, Chen T, Guan D, Li J, Wang J, Zhang E, Feng Y, Yin F, Yuan Y, Fang Y, Qiu L, Xie D, Wei D.

Biochem Biophys Res Commun. 2017 Jan 22;482(4):1048-1053. doi: 10.1016/j.bbrc.2016.11.156. Epub 2016 Nov 28.

PMID:
27908734
5.

Inhibition of triosephosphate isomerase by phosphoenolpyruvate in the feedback-regulation of glycolysis.

Grüning NM, Du D, Keller MA, Luisi BF, Ralser M.

Open Biol. 2014 Mar 5;4:130232. doi: 10.1098/rsob.130232.

6.

The E104D mutation increases the susceptibility of human triosephosphate isomerase to proteolysis. Asymmetric cleavage of the two monomers of the homodimeric enzyme.

De La Mora-De La Mora I, Torres-Larios A, Mendoza-Hernández G, Enriquez-Flores S, Castillo-Villanueva A, Mendez ST, Garcia-Torres I, Torres-Arroyo A, Gómez-Manzo S, Marcial-Quino J, Oria-Hernández J, López-Velázquez G, Reyes-Vivas H.

Biochim Biophys Acta. 2013 Dec;1834(12):2702-11. doi: 10.1016/j.bbapap.2013.08.012. Epub 2013 Sep 20.

PMID:
24056040
7.

The pathophysiology of triose phosphate isomerase dysfunction in Alzheimer's disease.

Tajes M, Guivernau B, Ramos-Fernández E, Bosch-Morató M, Palomer E, Guix FX, Muñoz FJ.

Histol Histopathol. 2013 Jan;28(1):43-51. doi: 10.14670/HH-28.43. Review.

PMID:
23233058
8.

Energy metabolism and ageing regulation: metabolically driven deamidation of triosephosphate isomerase may contribute to proteostatic dysfunction.

Hipkiss AR.

Ageing Res Rev. 2011 Sep;10(4):498-502. doi: 10.1016/j.arr.2011.05.003. Epub 2011 May 30. Review.

PMID:
21651995
9.

Triosephosphate isomerase deficiency: a patient with Val231Met mutation.

Serdaroglu G, Aydinok Y, Yilmaz S, Manco L, Ozer E.

Pediatr Neurol. 2011 Feb;44(2):139-42. doi: 10.1016/j.pediatrneurol.2010.08.016.

PMID:
21215915
10.

Reappraisal of triosephosphate isomerase deficiency.

Orosz F, Oláh J, Ovádi J.

Eur J Haematol. 2011 Mar;86(3):265-7. doi: 10.1111/j.1600-0609.2010.01484.x. No abstract available.

PMID:
20546019
11.

Triose phosphate isomerase deficiency associated with two novel mutations in TPI gene.

Fermo E, Bianchi P, Vercellati C, Rees DC, Marcello AP, Barcellini W, Zanella A.

Eur J Haematol. 2010 Aug;85(2):170-3. doi: 10.1111/j.1600-0609.2010.01451.x. Epub 2010 Mar 31.

PMID:
20374271
12.

Analysis of TPI gene promoter variation in three sub-Saharan Africa population samples.

Manco L, Machado P, Lopes D, Nogueira F, Do Rosário VE, Alonso PL, Varandas L, Trovoada Mde J, Amorim A, Arez AP.

Am J Hum Biol. 2009 Jan-Feb;21(1):118-20. doi: 10.1002/ajhb.20819.

PMID:
18792062
13.

Structural basis of human triosephosphate isomerase deficiency: mutation E104D is related to alterations of a conserved water network at the dimer interface.

Rodríguez-Almazán C, Arreola R, Rodríguez-Larrea D, Aguirre-López B, de Gómez-Puyou MT, Pérez-Montfort R, Costas M, Gómez-Puyou A, Torres-Larios A.

J Biol Chem. 2008 Aug 22;283(34):23254-63. doi: 10.1074/jbc.M802145200. Epub 2008 Jun 18.

14.

Sequencing and genotypic analysis of the triosephosphate isomerase (TPI1) locus in a large sample of long-lived Germans.

Ralser M, Nebel A, Kleindorp R, Krobitsch S, Lehrach H, Schreiber S, Reinhardt R, Timmermann B.

BMC Genet. 2008 May 29;9:38. doi: 10.1186/1471-2156-9-38.

15.

Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis.

Wang X, Lu Y, Yang J, Shi Y, Lan M, Liu Z, Zhai H, Fan D.

J Cancer Res Clin Oncol. 2008 Sep;134(9):995-1003. doi: 10.1007/s00432-008-0367-5. Epub 2008 Feb 29.

PMID:
18309519
16.

Triose phosphate isomerase deficiency is caused by altered dimerization--not catalytic inactivity--of the mutant enzymes.

Ralser M, Heeren G, Breitenbach M, Lehrach H, Krobitsch S.

PLoS One. 2006 Dec 20;1:e30.

17.

Anti-triosephosphate isomerase antibodies in cerebrospinal fluid are associated with neuropsychiatric lupus.

Sasajima T, Watanabe H, Sato S, Sato Y, Ohira H.

J Neuroimmunol. 2006 Dec;181(1-2):150-6. Epub 2006 Oct 24.

PMID:
17064784
18.

Triosephosphate isomerase deficiency: consequences of an inherited mutation at mRNA, protein and metabolic levels.

Oláh J, Orosz F, Puskás LG, Hackler L Jr, Horányi M, Polgár L, Hollán S, Ovádi J.

Biochem J. 2005 Dec 15;392(Pt 3):675-83.

19.

Antibodies to triosephosphate isomerase in patients with neuropsychiatric lupus.

Watanabe H, Seino T, Sato Y.

Biochem Biophys Res Commun. 2004 Sep 3;321(4):949-53.

PMID:
15358119
20.

Proteomic surveillance of autoimmunity in osteoarthritis: identification of triosephosphate isomerase as an autoantigen in patients with osteoarthritis.

Xiang Y, Sekine T, Nakamura H, Imajoh-Ohmi S, Fukuda H, Nishioka K, Kato T.

Arthritis Rheum. 2004 May;50(5):1511-21.

Supplemental Content

Support Center